Methylprednisolon ( DrugBank: Methylprednisolon )

4 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
13	多発性硬化症／視神経脊髄炎	58
14	慢性炎症性脱髄性多発神経炎／多巣性運動ニューロパチー	2
51	全身性強皮症	10
66	IgA腎症	11

13. 多発性硬化症／視神経脊髄炎

臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

diseases per page:

Showing 1 to 10 of 58 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05232825 (ClinicalTrials.gov)	May 3, 2022	27/1/2022	A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investiga ...	A Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical ...	Relapsing Multiple Sclerosis;Primary Progressive Multiple Sclerosis	Drug: Ocrelizumab IV;Drug: Ocrelizumab SC;Drug: Methylprednisolone IV;Drug: Diphenhydramine IV;Drug: ...	Hoffmann-La Roche	NULL	Active, not recruiting	18 Years	65 Years	All	234	Phase 3	United States;Australia;Brazil;Czechia;Italy;New Zealand;Poland;Spain;Turkey;Canada;Russian Federati ...
2	NCT04979650 (ClinicalTrials.gov)	May 22, 2021	2/7/2021	Corticosteroid Effects on Asymptomatic Gadolinium-enhancing Lesions in Multiple Sclerosis	Corticosteroid Pulse Therapy Effects on MRI Asymptomatic Gadolinium-enhancing Lesions Conversion to ...	Multiple Sclerosis, Relapsing-Remitting;Magnetic Resonance Imaging;Methylprednisolone	Drug: Methylprednisolone succinate;Drug: Normal saline	Mazandaran University of Medical Sciences	NULL	Enrolling by invitation	18 Years	55 Years	All	104	Phase 2	Iran, Islamic Republic of
3	NCT04688788 (ClinicalTrials.gov)	April 28, 2021	22/12/2020	Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis	Danish Non-inferiority Study of Ocrelizumab and Rituximab in MS (DanNORMS): A Randomized Study Compa ...	Relapsing Remitting Multiple Sclerosis;Secondary Progressive Multiple Sclerosis;Primary Progressive ...	Drug: Rituximab;Drug: Ocrelizumab;Drug: Fexofenadine;Drug: Paracetamol;Drug: Methylprednisolone	Rigshospitalet, Denmark	Odense University Hospital;Aarhus University Hospital;Aalborg University Hospital;Herlev Hospital;Hi ...	Recruiting	18 Years	65 Years	All	594	Phase 3	Denmark
4	NCT04548999 (ClinicalTrials.gov)	December 3, 2020	9/9/2020	A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adu ...	A Phase IIIB Multicenter, Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy, Safet ...	Multiple Sclerosis	Drug: Ocrelizumab;Drug: Antihistamine;Drug: Methylprednisolone	Hoffmann-La Roche	NULL	Recruiting	18 Years	55 Years	All	699	Phase 3	United States;Argentina;Belgium;Brazil;Bulgaria;Canada;Czechia;Denmark;France;Germany;Greece;Hungary ...
5	NCT04544436 (ClinicalTrials.gov)	November 26, 2020	4/9/2020	A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adu ...	A Phase IIIb Multicenter, Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy, Safet ...	Multiple Sclerosis	Drug: Ocrelizumab;Drug: Antihistamine;Drug: Methylprednisolone	Hoffmann-La Roche	NULL	Recruiting	18 Years	55 Years	All	865	Phase 3	United States;Argentina;Australia;Belgium;Brazil;Canada;Czechia;Denmark;France;Germany;Greece;Hungar ...
6	NCT04601142 (ClinicalTrials.gov)	October 31, 2020	15/10/2020	Association Between the Effect of Glucocorticoid Pulse Therapy on Neuromyelitis Optica (NMO) and Gen ...	Study on the Association Between the Effect of Glucocorticoid Pulse Therapy on Neuromyelitis Optica ...	Glucocorticoid Resistance;Gene;Neuromyelitis Optica	Drug: Methylprednisolone	Beijing Tongren Hospital	NULL	Recruiting	16 Years	80 Years	All	350		China
7	EUCTR2018-000620-34-DE (EUCTR)	06/05/2020	08/11/2019	Imatinib treatment for Multiple Sclerosis (MS) Relapses	Imatinib for Multiple Sclerosis (MS) Relapses - a Phase II, Randomised Study - Imatinib MS	Patients with clinically definite Multiple Sclerosis (MS) according to the McDonald Criteria, or pos ...	INN or Proposed INN: IMATINIB MESILATE INN or Proposed INN: Methylprednisolone Other descriptive name: ...	Department of Clinical Neuroscience, Karolinska Institutet	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	200	Phase 2	Germany;Sweden
8	NCT03829566 (ClinicalTrials.gov)	November 2019	1/2/2019	Autologous Transplant To End NMO Spectrum Disorder	Autologous Hematopoietic Stem Cell Transplant for Neuromyelitis Optica Spectrum Disorder (NMOSD)	Neuromyelitis Optica;Devic's Disease;NMO Spectrum Disorder	Drug: Rituximab;Drug: Cyclophosphamide;Drug: Mesna;Drug: rATG;Drug: Methylprednisolone;Drug: G-CSF;B ...	Northwestern University	NULL	Withdrawn	18 Years	65 Years	All	0	Phase 2/Phase 3	United States
9	NCT02769689 (ClinicalTrials.gov)	June 12, 2019	17/3/2016	Methylprednisolone During the Switch Between Natalizumab and Fingolimod	Once a Month High-dose Methylprednisolone During Wash-out Period Between Natalizumab and Fingolimod ...	Multiple Sclerosis	Drug: Methylprednisolone;Drug: Placebo;Drug: natalizumab (NTZ);Drug: fingolimob (FTY)	University Hospital, Clermont-Ferrand	NULL	Recruiting	18 Years	65 Years	All	56	Phase 4	France
10	NCT03674099 (ClinicalTrials.gov)	October 1, 2018	14/9/2018	Imatinib for Multiple Sclerosis (MS) Relapses	Imatinib for Multiple Sclerosis (MS) Relapses - a Phase II, Randomised Study	Multiple Sclerosis	Drug: Imatinib Mesylate;Drug: Methylprednisolone	Tomas Olsson	The Swedish Research Council	Recruiting	18 Years	55 Years	All	200	Phase 2	Denmark;Germany;Norway;Sweden

First Previous1 2 3 4 5 6Next Last

先頭へ

14. 慢性炎症性脱髄性多発神経炎／多巣性運動ニューロパチー

臨床試験数 : 175 / 薬物数 : 161 - (DrugBank : 41) / 標的遺伝子数 : 13 - 標的パスウェイ数 : 24

diseases per page:

Showing 1 to 2 of 2 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2017-002511-34-GB (EUCTR)	01/04/2019	08/11/2019	Initial treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) - combined immunoglobu ...	Intravenous immunoglobulin and intravenous methylprednisolone as optimal induction treatment in CIDP ...	Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) MedDRA version: 21.1;Level: PT;Classificati ...	Trade Name: methylprednisolone Product Name: methylprednisolone Trade Name: sodium chloride 0.9% Produc ...	Academic Medical Centre, Amsterdam, NL	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	96	Phase 3	Netherlands;United Kingdom
2	EUCTR2017-002511-34-NL (EUCTR)	26/09/2018	17/04/2018	Intravenous immunoglobulin and intravenous methylprednisolone as optimal induction treatment in CIDP ...	Intravenous immunoglobulin and intravenous methylprednisolone as optimal induction treatment in CIDP ...	Chronic inflammatory demyelinating polyneuropathy (CIDP);Therapeutic area: Diseases [C] - Nervous Sy ...	Trade Name: Methylprednisolone (Solu-Medrol) Product Name: Methylprednisolon(Solu-Medrol) Trade Name: ...	Academisch Medisch Centrum	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	96	Phase 3	Netherlands

First Previous1Next Last

51. 全身性強皮症

臨床試験数 : 525 / 薬物数 : 565 - (DrugBank : 148) / 標的遺伝子数 : 114 - 標的パスウェイ数 : 217

diseases per page:

Showing 1 to 10 of 10 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2015-004613-24-BE (EUCTR)	17/07/2019	18/04/2019	Hit hard and early. The effect of high dose methylprednisolonon nailfold capillary changes and bioma ...	Hit hard and early. The effect of high dose methylprednisolonon nailfold capillary changes and bioma ...	(very early) systemic sclerosis;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: Solu-Medrol Product Name: methylprednisolon INN or Proposed INN: METHYLPREDNISOLONE SODIUM ...	Radboudumc	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	30	Phase 4	Belgium;Netherlands
2	NCT03742466 (ClinicalTrials.gov)	November 10, 2018	10/11/2018	Local Injection of Ozone Versus Methylprednisolone Acetate in Carpal Tunnel Syndrome of Scleroderma ...	Local Injection of Ozone Versus Methylprednisolone Acetate in Carpal Tunnel Syndrome of Scleroderma ...	Carpal Tunnel Syndrome;Chronic Pain;Scleroderma	Drug: Ozone;Drug: methylprednisolone acetate	Assiut University	NULL	Completed	20 Years	60 Years	All	50	N/A	Egypt
3	NCT03593902 (ClinicalTrials.gov)	May 17, 2018	28/6/2018	Cardiac Safe Transplants for Systemic Sclerosis	Autologous Hematopoietic Stem Cell Transplant for Patients With Systemic Sclerosis and Cardiac Dysfu ...	Systemic Sclerosis;Scleroderma	Drug: Rituximab;Drug: Fludarabine;Drug: Cyclophosphamide;Drug: Mesna;Drug: rATG;Drug: Methylpredniso ...	Northwestern University	NULL	Terminated	18 Years	65 Years	All	9	Phase 2/Phase 3	United States
4	NCT03059979 (ClinicalTrials.gov)	January 2017	25/1/2017	The Effect of High Dose Methylprednisolone on Nailfold in Early Systemic Sclerosis ( SSc )	Hit Hard and Early. The Effect of High Dose Methylprednisolone on Nailfold Capillary Changes and Bio ...	Systemic Sclerosis;Raynaud Phenomena	Drug: Methylprednisolone;Other: sodium chloride	Radboud University	NULL	Recruiting	18 Years	N/A	All	30	Early Phase 1	Netherlands
5	EUCTR2015-004613-24-NL (EUCTR)	30/05/2016	13/04/2016	Hit hard and early	Hit hard and early. The effect of high dose methylprednisolonon nailfold capillary changes and bioma ...	(very early) systemic sclerosis;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: methylprednisolon INN or Proposed INN: methylprednisolon Other descriptive name: METHYLP ...	Radboudumc	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes		Phase 4	Netherlands
6	NCT01445821 (ClinicalTrials.gov)	September 15, 2011	29/9/2011	Autologous Stem Cell Systemic Sclerosis Immune Suppression Trial	Randomized Study of Different Non-myeloablative Conditioning Regimens With Hematopoietic Stem Cell S ...	Scleroderma, Systemic	Biological: Peripheral Blood Stem Cells;Drug: Cyclophosphamide;Drug: Mesna;Drug: rATG;Drug: Methylpr ...	Northwestern University	NULL	Terminated	17 Years	60 Years	All	44	Phase 3	United States
7	NCT01086540 (ClinicalTrials.gov)	June 24, 2011	11/3/2010	Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)	A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody ...	Systemic Sclerosis-Associated PAH	Biological: Rituximab;Other: Placebo;Diagnostic Test: CMRI;Drug: prednisone;Drug: methylprednisolone ...	National Institute of Allergy and Infectious Diseases (NIAID)	Autoimmunity Centers of Excellence;Rho Federal Systems Division, Inc.	Completed	18 Years	75 Years	All	57	Phase 2	United States
8	EUCTR2006-004598-83-GB (EUCTR)	22/10/2008	24/10/2008	High dose immunoablation and autologous hematopoietic stem cell transplantation versus monthly intra ...	High dose immunoablation and autologous hematopoietic stem cell transplantation versus monthly intra ...	Severe systemic sclerosis MedDRA version: 9.1;Level: LLT;Classification code 10042953;Term: Systemic ...	Trade Name: Cyclophosphamide Product Name: Cyclophosphamide INN or Proposed INN: CYCLOPHOSPHAMIDE Trade ...	EBMT (European group for Blood and Marrow Transplantation)	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	150		United Kingdom
9	EUCTR2008-000224-27-GB (EUCTR)	15/10/2008	07/08/2008	Systemic sclerosis associated interstitial lung disease: A longitudinal observational study assessin ...	Systemic sclerosis associated interstitial lung disease: A longitudinal observational study assessin ...	Systemic Sclerosis associated interstitial lung disease MedDRA version: 9.1;Level: LLT;Classificatio ...	Trade Name: Solu-medrone Product Name: methylprednisolone INN or Proposed INN: METHYLPREDNISOLONE Produ ...	Newcastle upon Tyne NHS Foundation Trust	NULL	Not Recruiting			Female: yes Male: yes	20	Phase 4	United Kingdom
10	NCT00379431 (ClinicalTrials.gov)	November 27, 2006	20/9/2006	A Protocol Based Treatment for Early and Severe Systemic Sclerosis With (Anti-CD20), Rituximab	A Protocol Based Treatment for Early and Severe Systemic Sclerosis With (Anti-CD20), Rituximab	Early and Severe Systemic Sclerosis	Drug: Administration of rituximab and methylprednisolone	University Hospital, Ghent	NULL	Completed	18 Years	N/A	All	9	Phase 2	Belgium

First Previous1Next Last

先頭へ

66. IgA腎症

臨床試験数 : 275 / 薬物数 : 258 - (DrugBank : 82) / 標的遺伝子数 : 36 - 標的パスウェイ数 : 140

diseases per page:

Showing 1 to 10 of 11 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04833374 (ClinicalTrials.gov)	May 24, 2021	4/4/2021	Steroids Therapy in IgA Nephropathy With Crescents	Effect and Security of Steroids Therapy for Patients of IgA Nephropathy With Crescents : A Prospecti ...	IgA Nephropathy	Drug: Methylprednisolone	Sixth Affiliated Hospital, Sun Yat-sen University	NULL	Recruiting	14 Years	65 Years	All	200	Phase 3	China
2	EUCTR2016-004507-31-FR (EUCTR)	27/01/2017	02/02/2017	N/A	N/A - TIGER	MedDRA version: 19.1;Level: PT;Classification code 10021263;Term: IgA nephropathy;System Organ Clas ...	Trade Name: METHYLPREDNISOLONE MYLAN Générique Product Name: METHYLPREDNISOLONE MYLAN Générique INN or ...	ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	122	Phase 3	France
3	NCT02647255 (ClinicalTrials.gov)	March 2016	21/12/2015	Trial of Plasma Exchange for Severe Crescentic IgA Nephropathy	Randomized Trial of Plasma Exchange as Adjunctive Therapy for Severe Crescentic GlomerUlonephritis o ...	Glomerulonephritis, IGA;Kidney Diseases;Acute Renal Insufficiency;Rapidly Progressive Glomerulonephr ...	Procedure: Plasma Exchange (PE);Drug: Methylprednisolone pulse	Peking University First Hospital	NULL	Terminated	14 Years	65 Years	All	10	Phase 2/Phase 3	China
4	NCT02160132 (ClinicalTrials.gov)	June 2014	3/6/2014	A Controlled Study of Steroids Therapy for Patients of IgA Nephropathy With Active Pathological Chan ...	Effect and Security of Steroids Therapy for Patients of IgA Nephropathy With Active Pathological Cha ...	Glomerulonephritis, IGA;Peripapillary Crescent;Necrosis;Steroid Nephropathy	Drug: Methylprednisolone(intravenously in the 1st-2nd-3rd month );Drug: Methylprednisolone(intraveno ...	Sun Yat-sen University	NULL	Recruiting	14 Years	65 Years	Both	180	Phase 2	China
5	NCT01560052 (ClinicalTrials.gov)	May 5, 2012	15/3/2012	Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study (TESTING Low Dose Study)	Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study Low Dose Study	IgA Glomerulonephritis	Drug: methylprednisolone;Drug: Placebo	The George Institute	Peking University First Hospital	Completed	18 Years	N/A	All	503	N/A	Australia;Canada;China;Hong Kong;India;Malaysia
6	ChiCTR-TRC-09000607	2008-12-01	2009-11-28	Observation for Efficacy of methylprednisolone and combined therapy of methylprednisolone and mycoph ...	Efficacy Observation of methylprednisolone and combined therapy of methylprednisolone and mycophenol ...	IgA nephropathy	A:Methylprednisolone 0.4mg/kg * 8 weeks, reduction to 5mg / d to maintain, MMF 0.75 bid * 6 months a ...	Zhongshan Hospital of Fudan University	NULL	Completed	18	70	Both	A:40;B:40;		China
7	EUCTR2007-000871-41-DE (EUCTR)	24/01/2008	27/11/2007	Supportive versus Immunosuppressive Therapy for the treatment Of Progressive IgA Nephropathy - STOP ...	Supportive versus Immunosuppressive Therapy for the treatment Of Progressive IgA Nephropathy - STOP ...	IgA nephropathy (IgAN) as the most common type of glomerulonephritis. MedDRA version: 16.1;Level: PT ...	Product Name: Azathioprine INN or Proposed INN: AZATHIOPRINE Product Name: Cyclophosphamid INN or Propo ...	RWTH Aachen	NULL	Not Recruiting			Female: yes Male: yes	148		Germany
8	NCT00657059 (ClinicalTrials.gov)	September 2007	8/4/2008	Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy (IgAN)	A Prospective, Multicenter, Randomized Controlled Trial of Mycophenolate Mofetil (MMF) in Patients W ...	IgA Nephropathy	Drug: irbesartan;Drug: methylprednisolone (MP) or prednisone (pred);Drug: mycophenolate mofetil (MMF ...	Sun Yat-sen University	NULL	Completed	14 Years	60 Years	All	151	Phase 3	China
9	JPRN-UMIN000000593	2006/11/01	05/02/2007	Randomized controlled trial of mizoribine for progressive IgA nephropathy	Randomized controlled trial of mizoribine for progressive IgA nephropathy - Randomized controlled tr ...	IgA nephropathy with moderate to severe histological alterations	Methylprednisolone pulse therapy followed by oral prednisolone administration Methylprednisolone puls ...	West Japan Study Group for Therapy of IgA Nephropathy	NULL	Complete: follow-up complete	15years-old	60years-old	Male and Female	120	Not selected	Japan
10	NCT01392833 (ClinicalTrials.gov)	December 1999	5/7/2011	Steroids and Azathioprine in Advanced IgAN	Steroids and Azathioprine in Early and Advanced IgA Nephropathy: Amendments to a Prospective Randomi ...	IgA Nephropathy;Chronic Kidney Disease	Drug: methylprednisolone;Drug: azathioprine;Drug: prednisone	A. Manzoni Hospital	NULL	Completed	16 Years	70 Years	Both	46	Phase 3	NULL

First Previous1 2Next Last

先頭へ